43:I[185,["/_next/static/chunks/0sxns9k8ywops.js","/_next/static/chunks/11fk-1ie3w6mp.js","/_next/static/chunks/1uc4qdk4uj22c.js","/_next/static/chunks/0jvahffpql9nd.js","/_next/static/chunks/0agcep-t686m_.js","/_next/static/chunks/2_mrasy1s2owt.js","/_next/static/chunks/1nsk8jrr9fqe6.js"],"SendEmailButton"] 45:I[63625,["/_next/static/chunks/0sxns9k8ywops.js","/_next/static/chunks/11fk-1ie3w6mp.js","/_next/static/chunks/1uc4qdk4uj22c.js","/_next/static/chunks/0jvahffpql9nd.js","/_next/static/chunks/0agcep-t686m_.js","/_next/static/chunks/2_mrasy1s2owt.js","/_next/static/chunks/1nsk8jrr9fqe6.js"],"AddToLibraryButton"] 46:I[29721,["/_next/static/chunks/0sxns9k8ywops.js","/_next/static/chunks/11fk-1ie3w6mp.js","/_next/static/chunks/1uc4qdk4uj22c.js","/_next/static/chunks/0jvahffpql9nd.js","/_next/static/chunks/0agcep-t686m_.js","/_next/static/chunks/2_mrasy1s2owt.js","/_next/static/chunks/1nsk8jrr9fqe6.js"],"ShareButton"] 47:I[58016,["/_next/static/chunks/0sxns9k8ywops.js","/_next/static/chunks/11fk-1ie3w6mp.js","/_next/static/chunks/1uc4qdk4uj22c.js","/_next/static/chunks/0jvahffpql9nd.js","/_next/static/chunks/0agcep-t686m_.js","/_next/static/chunks/2_mrasy1s2owt.js","/_next/static/chunks/1nsk8jrr9fqe6.js"],"ProcessEpisodeButton"] 48:I[45269,["/_next/static/chunks/0sxns9k8ywops.js","/_next/static/chunks/11fk-1ie3w6mp.js","/_next/static/chunks/1uc4qdk4uj22c.js","/_next/static/chunks/0jvahffpql9nd.js","/_next/static/chunks/0agcep-t686m_.js","/_next/static/chunks/2_mrasy1s2owt.js","/_next/static/chunks/1nsk8jrr9fqe6.js"],"SignupCTA"] 3b:["$","time",null,{"dateTime":"2026-06-16T00:00:00.000Z","children":"June 16, 2026"}] 3c:["$","span",null,{"aria-hidden":true,"children":"·"}] 3d:["$","span",null,{"children":"00:25:13"}] 44:T513,

Biotech IPOs that are getting out remain hot — but will that continue into the fall? On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the market for fresh biotech paper on NASDAQ, including the $770 million debut by Parabilis, the largest IPO in the sector’s history.
The analysts also discuss the Biosecure Act and U.S. policy toward China; the cachexia pipeline; and BioCentury’s updated Innovation Distillery.

View full story: https://www.biocentury.com/article/659773

#BiotechIPO #NASDAQ #BiosecureAct #Cachexia #ChinaBiotech

00:36 - Innovation Distillery
03:56 - Biotech IPOs
10:13 - Biosecure Act, WuXi AppTec
16:03 - Cachexia Pipeline
22:03 - Ouster for RFK Jr.?

To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.

Reach us by sending a text